سعر انليتا 5مجم 56 قرص 2026

Inlyta 5 mg film-coated tablets (pack of 56): axitinib, an oral VEGFR tyrosine kinase inhibitor used for advanced renal cell carcinoma, by Pfizer.

• First-line treatment of advanced renal cell carcinoma in combination with avelumab.Population: AdultsDailyMed (U.S. National Library of Medicine)
• First-line treatment of advanced renal cell carcinoma in combination with pembrolizumab.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Single-agent treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>=20%) as a single agent include diarrhoea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysaesthesia, weight loss, vomiting, asthenia and constipation; with avelumab or pembrolizumab also hepatotoxicity, hypothyroidism, mucositis/stomatitis, rash and cough.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• The US label lists no contraindications.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypertension, including hypertensive crisis: blood pressure should be well controlled before starting; monitor and treat; withhold, reduce or permanently discontinue according to severity.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Arterial and venous thromboembolic events, which can be fatal: use with caution in patients at increased risk; permanently discontinue after an arterial thromboembolic event.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Haemorrhage, including fatal events: not studied in untreated brain metastasis or recent active gastrointestinal bleeding and should not be used in those patients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4/5 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole)Increase axitinib exposure; avoid. If co-administration is unavoidable, reduce the axitinib dose by about half and return to the previous dose 3-5 half-lives after the inhibitor is stopped.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4/5 inducers (e.g. rifampin, dexamethasone, phenytoin, carbamazepine, phenobarbital, St John's wort)Reduce axitinib exposure; avoid. Moderate inducers (e.g. bosentan, efavirenz, modafinil) should also be avoided if possible.DailyMed (U.S. National Library of Medicine)
• Grapefruit / grapefruit juiceMay increase axitinib plasma concentrations; avoid.DailyMed (U.S. National Library of Medicine)

• Based on animal findings and mechanism of action, axitinib can cause fetal harm; there are no human data; axitinib was teratogenic, embryotoxic and fetotoxic in mice at exposures below human exposure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; advise women not to breastfeed during treatment and for 2 weeks after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Axitinib: Inhibits receptor tyrosine kinases including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2 and VEGFR-3, which are implicated in pathologic angiogenesis and tumour growth (US label 12.1).